# Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

> **NCT02547844** · PHASE4 · COMPLETED · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 30 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** efavirenz + emtricitabina + tenofovir
- **DRUG:** rilpivirina + emtricitabina + tenofovir

## Key facts

- **NCT ID:** NCT02547844
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547844, "Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02547844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*